Partial PTEN deletion is linked to poor prognosis in breast cancer

P. Lebok, V. Kopperschmidt, M. Kluth, C. Hube-Magg, C. Özden, Taskin B., K. Hussein, A. Mittenzwey, A. Lebeau, I. Witzel, L. Wölber, S. Mahner, F. Jänicke, S. Geist, P. Paluchowski, C. Wilke, U. Heilenkötter, Ronald Simon, Guido Sauter, L. Terracciano, R. Krech, A. von d. Assen, V. Müller and E. Burandt

Abstract

Background: Deletions of chromosome 10q23, including the PTEN (phosphatase and tensin homolog) locus, are known to occur in breast cancer, but systematic analyses of its clinical relevance are lacking.

Methods: We thus analyzed a tissue microarray (TMA) with 2,197 breast cancers by fluorescence in-situ hybridization (FISH) using a PTEN-specific probe.

Results: PTEN deletions were detected in 19% of no special type, 9% of lobular, 4% of tubular cancers and 46% in carcinomas with medullary features. 98.7% of deletions were heterozygous and only 1.3% were homozygous. PTEN deletion was significantly linked to advanced tumor stage (p = 0.0054), high-grade (p < 0.0001), high tumor cell proliferation (Ki67 Labeling Index; p < 0.0001), and shortened overall survival (p = 0.0090). PTEN deletions were inversely associated with features of luminal type breast cancers (ER/PR positivity; p < 0.0001 each, and CCND1 amplification; p = 0.0020). PTEN deletions were also strongly linked to amplification of genes involved in the PTEN/AKT pathway such as MYC (p = 0.0430) and HER2 (p = 0.0065). Remarkably the combined analysis of MYC, HER2, CCND1 and PTEN aberrations suggested that aberrations of multiple PTEN/AKT pathway genes have a strong additive effect on breast cancer prognosis. While cancers with one of these aberrations behaved only marginally different from cancers with none, disease outcome was markedly worse in cancers with two or more aberrations as compared to those with only one aberration (p = 0.0002). In addition, the particularly poor prognosis of patients with HER2 amplification and PTEN deletions challenges the concept of PTEN deletions interfering with trastuzumab therapy.

Conclusion: PTEN deletion occurs in a relevant fraction of breast cancers, and is linked to aggressive tumor behavior. Reduced PTEN function cooperates with MYC and HER2 activation in conferring aggressive phenotype to cancer cells.

Keywords: Breast cancer, PTEN, FISH, Prognosis

Background

Breast cancer is the most common carcinoma detected in women, accounting for about one fifth of new cancer cases in females [1]. Surgical removal of the cancer represents the standard of care followed by radiation and/or adjuvant therapy in patients considered to be at particular risk for persistent local or systemic disease. Histopathological parameters are of particular importance for assessing tumor aggressiveness. This especially applies for pathological stage (pT), histologic grade, and nodal stage (pN). Although powerful in statistical analyses, these parameters are not sufficient to predict the prognosis of individual patients reliably enough in all cases.

Analysis of molecular features in cancer cells bears the potential of providing a better estimation of the prognosis than classical pathological parameters alone [2–4].

The PTEN gene at 10q23 encodes a lipid phosphatase that functions as a direct antagonist of phosphatidylinositol 3-kinase and is involved in the regulation of the AKT pathway. Inactivation of PTEN leads to constitutively activated levels of AKT, thus promoting cell growth, proliferation, survival and migration through multiple downstream effectors [5]. PTEN is one of the most frequently deleted genes in various human cancer types [6], and alterations of...
PTEN were reported to have prognostic relevance in gastric cancer [7], colorectal cancer [8], non-small cell lung cancer [9], diffuse large B-cell lymphoma [10], mesothelioma [11] and prostate cancer [12].

In breast cancer - despite various earlier studies - frequency and relevance of PTEN alterations is unclear. The frequency of PTEN deletions or reduced expression varies from 4 % to 63 % in the literature [13, 14]. Some studies on 99–151 breast cancer patients have suggested associations between PTEN inactivation and poor prognosis [15–17], but this could not be confirmed in other studies involving 212–670 cancers [18–20]. In addition, PTEN deletion has been intensively discussed as a potential predictor for failure of anti-HER2 therapy [21–23].

To better understand the clinical relevance of PTEN deletions in breast cancer we analyzed more than 2,100 breast cancers with clinical follow-up data. Fluorescence in-situ hybridization (FISH) was applied for PTEN analysis because FISH is the gold standard for analyzing DNA copy number changes. Moreover, to better understand the role of PTEN deletions in cancers with HER2 amplification we analyzed a historical cohort of cancers that was collected before anti-HER2 treatments were routinely applied to women with HER2 positive breast cancer. Our data show that PTEN deletion is tightly linked to poor disease outcome and they suggest this also applies to the subgroup of HER2 positive cancers not treated with trastuzumab.

**Methods**

**Breast cancer tissue microarray**

A pre-existing tissue microarray (TMA) was used for the purpose of this study [24]. In short, one 0.6 mm core was taken from a representative tissue block from each patient. The tissues were distributed among 6 TMA blocks, each containing 263 to 522 tumor samples. The TMA contained in total 2,197 human breast cancer samples from paraffin-embedded tissue specimens fixed in 4 % neutral buffered formalin. The median patient’s age was 63 (range 26–101) years. The use of the specimens and data for research purposes was approved by local laws (HmbKHG, §12,1) and the local ethics committee (Ethics commission Ärztekammer Hamburg, WF-049/09 and PV3652). According to local laws, informed consent was not required for this study. Patient records/information was anonymized and de-identified prior to analysis. All work has been carried out in compliance with the Helsinki Declaration. Survival data were either obtained from the cancer registry of Basel or collected from the patients attending physicians. Raw survival data were available from 1,982 patients (713 patients with and 1,508 without event (death)). The mean follow-up time was 63 months (range 1–176 months). Tumor size and nodal status were obtained from the primary pathology reports. All slides from the tumors were reviewed by specialized pathologists to define the histologic grade according to Elston and Ellis [25] and the tumor type according to the WHO classification (WHO 2012). Four μm sections of the TMA blocks were transferred to an adhesive coated slide system (Instrumedics Inc., Hackensack, New Jersey) for FISH analysis. Molecular data used in this study were available from previously published studies. These included amplification data obtained by FISH for HER2, CCND1, and MYC as well as expression data obtained by immunohistochemistry for estrogen receptor (ER), progesteron receptor (PR) and Ki67 [24, 26].

**Fluorescence in-situ hybridization**

Four micrometer TMA sections were used for fluorescence in-situ hybridization (FISH). For proteolytic slide pretreatment, a commercial kit was used (paraffin pre-treatment reagent kit; Abbott, Wiesbaden, Germany). TMA sections were deparaffinized, air-dried, and dehydrated in 70 %, 85 %, and 100 % ethanol, followed by denaturation for 5 min at 74 °C in 70 % formamid 2x SSC solution. The home-made FISH probe set consisted of a spectrum-orange labeled PTEN probe (made from a mixture of BAC RP11-380G5 and BAC RP11-813O3), and a spectrum-green labeled commercial centromere 10 probe (#6)37-10; Abbott, Wiesbaden, Germany) as a reference. Hybridization was performed overnight at 37 °C in a humidified chamber. Slides were subsequently washed and counterstained with 0.2μmol/L 4’-6-diamidino-2-phenylindole in antifade solution. Stained slides were manually interpreted with an epifluorescence microscope (Axio Imager A1, Zeiss, Oberkochen, Germany), and the predominant FISH signal numbers were recorded in each tissue spot. Presence of fewer PTEN signals than centromere 10 probe signals in at least 60 % tumor nuclei were considered as heterozygous deletion. Complete absence of PTEN signals in the tumor cells, but presence of centromere 10 signals and PTEN signals in adjacent normal cells, was considered homozygous deletion (Fig. 1). Tissue spots lacking any detectable PTEN signals in all (tumor and normal cells) or lack of any normal cells as an internal control for successful hybridization of the FISH probe were excluded from analysis. These thresholds were based on our previous study analyzing PTEN deletions on a prostate cancer TMA [12].

**Statistics**

Statistical calculations were performed with JMP 9 software (SAS Institute Inc., NC, USA). Contingency table analysis and Chi square test were used to study the relationship between IHC and FISH results and clinicopathological variables. Kaplan–Meier plots were used to estimate disease-specific and overall survival and the statistical significance was determined by the log rank test. The log-Rank test was applied to test the significance of differences between stratified survival functions.
Results

**PTEN** deletion frequency

A total of 1,239 (56.4 %) of arrayed cancer samples were analyzable by FISH. **PTEN** deletions were found in 233 (19 %) interpretable breast cancers, including 17 % heterozygous and 2 % homozygous deletions.

**Association to breast cancer phenotype**

**PTEN** deletions were found in 19 % of NST cancers, 9 % of lobular \((p = 0.0036 \text{ vs NST})\), 35 % of papillary cancers \((p = 0.1150 \text{ vs NST})\) and 46 % of cancers with medullary features \((p = 0.0002 \text{ vs NST})\). If all cancers were jointly analyzed, deletion of **PTEN** were significantly linked to advance tumor stage \((p = 0.0054)\), and high histopathological grade \((p < 0.0001)\) in all cancers. These associations held also true in the largest subset of No Special Type (NST) cancers. In addition, **PTEN** deletions were strongly linked to the subset of hormone receptor (ER/PR) negative breast cancers: deletion was found in 43 % of ER negative and 24 % of PR negative but only in 11 % of ER negative and 11 % of PR positive breast cancers \((p < 0.0001 \text{ each})\). **PTEN** deletion was unrelated to presence of lymph node metastases. All results are summarized in Table 1.

**Association to amplifications of HER2, CCND1 and MYC**

**HER2**, **CCND1** and **MYC** amplification results were available from a previous study [24]. In total, FISH results on both **PTEN** deletions and amplifications of **HER2**, **CCND1** and **MYC** were available in subsets of 1,047 (**HER2**), 792 (**MYC**) and 1,149 (**CCND1**) cancers. There was a positive association between **PTEN** deletion and amplification of **HER2** and **MYC**, but an inverse association to amplification of **CCND1**. **PTEN** deletion was found in 27 % of 195 **HER2** amplified cancers but in only 18 % of 852 tumors with normal **HER2** copy numbers \((p = 0.0065)\), as well as in 26 % of 57 **MYC** amplified cancers but in only 17 % of 735 tumors with normal **MYC** copy numbers \((p = 0.0430)\). In contrast, **PTEN** deletion was found in only 12 % of 237 **CCND1** amplified cancers, but in 21 % of 912 tumors with normal **CCND1** copy numbers \((p = 0.0020)\). These associations are shown in detail in Fig. 2.

**Association with cell proliferation**

Data on the tumor cell proliferation, as determined by immunohistochemical analysis of the Ki67 antigen, were available from a previous study using the same TMA [24]. **PTEN** deletions were strongly associated with a high Ki67 labeling index (LI) if all cancers were jointly analyzed \((p < 0.0001)\), as well as in subsets of cancers with identical grade \((p < 0.05 \text{ each})\).

**Prognostic significance of **PTEN** deletion**

Data on raw survival were available from 1,236 cancers with interpretable **PTEN** FISH results. Presence of **PTEN** deletion was linked to shortened overall survival if all cancers were jointly analyzed \((p = 0.0090, \text{ Fig. 4a})\), as well as in the subsets of NST cancers \((p = 0.0629, \text{ Fig. 4b})\), and in the subset of NST cancers with nodal metastases \((p < 0.0001, \text{ Fig. 4c})\). To study, whether **PTEN** deletion has an additional prognostic value in cancers harboring co-amplification of **HER2**, **MYC**, or **CCND1**, we stratified cancers for survival analysis according to the status of **PTEN** and **HER2** (Fig. 5a), **PTEN** and **MYC** (Fig. 5b), as well as **PTEN** and **CCND1** (Fig. 5c). These analyses suggested an inferior prognosis in cancers harboring **PTEN** deletions with co-amplifications of **HER2**, **MYC**, or **CCND1** as compared to those without co-amplification, but the differences did not reach statistical significance. Since the failure to find significant differences was most likely due to small numbers in the various subsets, we combined all cancers according to the number of alterations, including **PTEN** deletion and amplification of any of **HER2**, **MYC**, or **CCND1**. In this combined analysis, we found a shortened survival for patients with cancers harboring alterations in 2 or more of these genes as compared to tumors with no or one alteration \((p = 0.0002, \text{ Fig. 5d})\).
Table 1 Clinico-pathological association of PTEN deletion

|                        | Analyzable (n) | PTEN FISH | P value |
|------------------------|----------------|-----------|---------|
|                        |                | normal    | deletion |
| All cancers            | 1239           | 81 %      | 19 %    |
| **Histology**          |                |           |         |
| No special type        | 917            | 81 %      | 19 %    | -       |
| Lobular carcinoma      | 123            | 91 %      | 9 %     | 0.005*  |
| Cribriform carcinoma   | 43             | 88 %      | 12 %    | 0.32    |
| Medullary carcinoma    | 39             | 54 %      | 46 %    | 0.0001  |
| Tubular carcinoma      | 28             | 96 %      | 4 %     | 0.04    |
| Papillary carcinoma    | 17             | 65 %      | 35 %    | 0.11    |
| Mucinous carcinoma     | 29             | 97 %      | 3 %     | 0.03    |
| Other rare types\*     | 43             | 58 %      | 42 %    | 0.007   |
| **pT stage**           |                |           |         |
| pT1                    | 411            | 87 %      | 13 %    | 0.005   |
| pT2                    | 613            | 78 %      | 22 %    |         |
| pT3                    | 61             | 77 %      | 23 %    |         |
| pT4                    | 146            | 79 %      | 21 %    |         |
| **BRE grade**          |                |           |         |
| Grade 1                | 308            | 93 %      | 7 %     | <0.0001 |
| Grade 2                | 472            | 87 %      | 13 %    |         |
| Grade 3                | 457            | 68 %      | 32 %    |         |
| **Nodal stage**        |                |           |         |
| pN0                    | 524            | 82 %      | 18 %    | 0.18    |
| pN1                    | 446            | 79 %      | 21 %    |         |
| pN2                    | 64             | 72 %      | 28 %    |         |
| **ER status**          |                |           |         |
| Negative               | 296            | 57 %      | 43 %    | <0.0001 |
| Positive               | 906            | 89 %      | 11 %    |         |
| **PR status**          |                |           |         |
| Negative               | 744            | 76 %      | 24 %    | <0.0001 |
| Positive               | 408            | 89 %      | 11 %    |         |

Abbreviations: pT Pathological tumor, BRE Breast cancer histologic, ER Estrogen receptor, PR Progesterone receptor, FISH Fluorescence in-situ hybridization
\* Including adenoid-cystic carcinoma, apocrine carcinoma, atypical medullary carcinoma, carcinosarcoma, clear cell carcinoma, histiocytic carcinoma, lipid rich carcinoma, lipid rich or histiocytic carcinoma, metaplastic carcinoma, neuroendocrine carcinoma, signet ring carcinoma, and small cell carcinoma
*: Versus cancers of no special type

Fig. 2 Associations between PTEN deletion and amplifications of HER2, MYC and CCND1 analyzed by FISH
Discussion

Analyzing more than 1,200 informative breast cancers using a FISH probe directed against the known tumor suppressor gene PTEN at 10q23, we found that PTEN deletion is strongly linked to poor patient prognosis.

PTEN deletion was found in 18.8% of breast cancers. These results are in the range of two earlier studies reporting PTEN deletions in 12%–19% of unselected breast cancers using FISH [27] or array CGH [16]. In our study, PTEN deletion was defined as “fewer PTEN signals than centromere 10 signals in at least 60% of all tumor cells”. These stringent criteria resulted in a 100% concordance of results found by FISH and comparative genomic hybridization in a previous PTEN study of our group in prostate cancer [12]. A higher PTEN deletion rate by FISH (41%) was only reported from a study on 199 highly selected metastatic breast cancers [28], as well as from heterozygosity (LOH) studies, reporting PTEN deletion in 30%–41% of 22–105 analyzed breast cancers [29–33]. LOH induced by unequal allele distribution in the case of triploid or aneuploid cancers or tumors with overrepresentation of chromosome 10 may contribute to the relatively high rates of PTEN losses in these studies. FISH represents the gold standard for gene copy number analysis, because FISH is independent of the purity of cancer tissue and chromosomal aberrations such as polysomy. Deletions can be analyzed on a cell-by-cell basis, and abnormalities can be detected in a few cells or even a single cell.

Numerous studies measured alterations of PTEN protein expression by IHC in breast cancer. These studies show highly discordant results, with PTEN loss ranging from 4%–63% in 33–670 analyzed breast cancers [13, 14, 18, 31]. Reasons for this variability might include inherent issues of IHC, as no validated antibody, threshold, or protocol is available yet for PTEN expression analysis by immunohistochemistry on FFPE tissue [34]. In a previous study, we tested a series of seven anti-PTEN antibodies, but found all of them unsuitable for reliable measurement of PTEN expression in formalin fixed prostate cancer tissues since no meaningful association was found between the staining level of these antibodies and presence of PTEN deletions or tumor phenotype [12]. Discordant results were also reported for RNA expression analysis by RT-PCR. Here studies reported loss of PTEN expression in 20% of 135 and 77% of 59 analyzed breast cancers [16, 27]. These discrepancies are not surprising, given that the results of such studies are substantially dependent on the purity of cancer tissue and the PTEN expression levels in normal breast epithelium, as well as in inflammatory or stromal cells.
PTEN deletions were unevenly distributed between breast cancer subtypes. Lobular cancers had a particularly low and cancers with medullary features had a markedly high rate of PTEN deletions as compared to NST cancers. This is a novel and unexpected observation, given that gene mutations of PTEN had been reported at similar rates in lobular (2 %) [35] and NST (2.3 %) carcinomas [36]. The high rate of PTEN deletions in cancers with medullary features fits well to the increased proliferation rate, which is one of the hallmarks of this kind of tumor [37]. However, it has been suggested that the favorable clinical course of cancers with medullary features may be strongly driven by a lower tendency for lymphovascular invasion and an activated immune defense that might overrule adverse genetic features [38, 39].

The data of our study show, that – at least in the largest subgroups of NST carcinomas - PTEN deletions are strongly linked to features of unfavorable tumor phenotype and to shortened overall survival. While most of the earlier studies on 22–258 breast cancers had also found associations with at least some phenotypic features of aggressive cancer [15–17, 30–33, 40], data were more conflicting with respect to patient outcome. The vast majority of studies analyzed the prognostic impact of PTEN alterations in NST cancers by immunohistochemistry [15–20, 41–43]. Half of these studies suggested a prognostic impact of lost or decreased PTEN expression in 99–182 tumors using overall survival, metastasis free-survival, disease-related death or recurrence-free survival as clinical endpoints [15–17, 43]. Other studies could not confirm a significant association between PTEN alterations and patient outcome using these clinical endpoints in 97–670 patients [18–20, 41, 42]. Only one study analyzed PTEN deletions by FISH in a set of 135 tumors [16]. In line with our analysis, this study revealed a strong link between PTEN deletion and reduced metastasis-free interval. Therefore our findings, in combination with the ease of measuring PTEN deletions by next generation sequencing methods, strongly prompt for including PTEN deletion measurement in future multiparametrical tests.

PTEN deletions were strongly linked to HER2 and MYC gene amplification in our patient set. Both HER2 and MYC are closely connected to AKT/PTEN signaling. MYC is a downstream effector of AKT-depended growth signaling but also controls AKT pathway activity in a negative feedback loop by up-regulation of PTEN [44]. Obviously, impairment of this control loop by deletion of PTEN can be expected to provide a growth advantage to cancer cells beyond MYC amplification alone. HER2 is one of the receptor tyrosine kinases upstream of PTEN. Since HER2 amplification strongly activates AKT signaling [45], the additional deletion of PTEN might confer a similar growth advantage to HER2 amplified cells as to MYC-amplified cells. In line with this notion, we found at least a strong trend towards an inferior prognosis for HER2 and/or MYC-amplified cancers with co-deletion of PTEN as compared to tumors harboring only one of these alterations.

Further in line with an important functional interaction between PTEN and HER2, it has been suggested that PTEN inactivation confers resistance to anti-HER2 agents.
therapies in cancers harboring HER2 amplification. Given that studies analyzing the impact of PTEN loss on trastuzumab response reported massively conflicting results [46], PTEN analysis has not been established as a clinical routine test prior to administration of trastuzumab. Some studies have suggested, that PTEN loss or reduced PTEN expression is sufficient to cause a decreased response to trastuzumab [47–49], whereas other studies found that an additional PIK3 mutation is required to confer resistance to anti-HER2 treatment [50, 51]. Additional studies did not find a relationship between PTEN alterations and sensitivity to trastuzumab [51, 52].

Whether or not PTEN alterations are of relevance for response to anti-HER2 therapies is of utmost relevance. Since PTEN deletion is found in a subset of 27 % of HER2 amplified cancers that are eligible for HER2 treatment, it can be estimated that PTEN deletion could potentially account for therapy failure in about one quarter of breast cancer patients receiving HER2 inhibitors. It is of note, however, that the generally poor prognosis of patients with the combination of both PTEN deletion and HER2 amplification as determined in a historical breast cancer patient set predating the era of anti-HER2 therapies demonstrates that the poor success of trastuzumab in PTEN deleted cancers may also be driven by increased cancer aggressiveness irrespective of therapy response.

The strong association of PTEN deletions with HER2 and MYC gene amplifications also fits well with the suggested role of PTEN in maintenance of genomic stability. PTEN is required for double strand breakage (DSB) repair by homologous recombination [53]. Consequently, PTEN has been termed “A new Guardian of the Genome” in reference to the crucial role of the p53 tumor suppressor for genome integrity [54]. Since erroneous DSB repair is one important prerequisite of DNA amplification by fusion bridge breakage [55], it seems likely that PTEN deletion contributes to development of gene amplification. Evidence for specific factors (such as for example PTEN inactivation) facilitating the development of genomic instability comes also from previous studies by others and us showing a nonrandom accumulation of amplifications

---

**Fig. 5** Association between patient survival and co-alterations: Kaplan Meier plots showing overall (raw) survival in cancers with alterations of a PTEN and HER2, b PTEN and MYC, c PTEN and CCND1, and d PTEN, HER2, MYC or CCND1. No alteration: neither PTEN deletion nor oncogene amplification, PTEN deletion only: deletion of PTEN but no oncogene amplification, oncogene amplification only: oncogene amplification but no PTEN deletion, PTEN deletion and oncogene amplification: concurrent alteration of both loci.
of different genomic regions, including HER2 and MYC, in a subset of breast cancers that are considered to show an “amplifier” phenotype [26, 56–59].

It is thus of note, that CCND1 amplifications were inversely linked to PTEN deletions in our study. This finding provides further evidence for the existence of molecularly distinct subsets of breast cancers, one of which may be linked to generalized genetic instability with accumulation of numerous genomic amplifications (including HER2 and MYC) as well as deletions (including PTEN), and another one that might develop CCND1 amplification by a more targeted mechanism. This noting is supported by the fact that CCND1 amplification is strongly linked to hormone receptor (ER/PR) positive breast cancers [60], while HER2 and/or MYC (like PTEN deletions in our study) are more often found in ER-negative than in ER-positive cancers [26, 61]. Such a putative instability-independent amplification mechanism may be driven by the synergistic actions of ER signaling and CCND1 in promoting cell cycle progression [62–64], and may include specific selection of cells with increased CCND1 copy numbers.

The results of our study demonstrate a marked impact of the deletion of one PTEN allele on breast cancer aggressiveness and prognosis. This finding is in line with several in-vivo studies demonstrating that deletion of one PTEN allele is sufficient to have substantial impact on cell biology. For example in mouse models, heterozygosity for PTEN leads to massively increased susceptibility to multiple tumor types [65–67], increased cell proliferation in the thyroid and prostate gland [65], and has been shown to cooperate with other genetic events, such as ERG fusion in murine prostate cancer [68, 69]. In an earlier study of 2,266 prostate cancers we had been able to demonstrate that no clinical difference existed between 225 patients with biallelic and 152 patients with monoallelic deletion of PTEN [12]. It was traditionally thought that chromosomal deletion is a mechanism to inactivate tumor suppressor genes in a two hit model for example in combination with a mutation of the other allele. However, large scale next generation sequencing of breast cancer genomes is increasingly demonstrating that mutations of “classical” tumor suppressor genes do not often accompany large deletions, suggesting that large deletions may not only serve for inactivation of a single gene [70]. Increasing evidence suggests that deletions impact affected cells by reduced dosage of multiple different genes residing on a certain chromosomal area. Studies in prostate cancer have demonstrated that various chromosomal deletions have marked prognostic relevance [12, 71–74]. As deletions are particularly frequent in breast cancer, it will be interesting to evaluate their clinical potential. This is all the more true, as deletions can relatively easy be studied by NGS even from formalin fixed material [75].

Conclusions

Our data identify PTEN deletions as a frequent event in breast cancer with marked prognostic impact. Given the strong association with HER2 amplification, and the putative role of PTEN inactivation for HER2 therapy failure, our findings prompt for further analysis to estimate the predictive value of PTEN deletion analysis for HER2 treatment success in breast cancer.

Abbreviations

BRE: Breast cancer histologic grade; ER: Estrogen receptor; FISH: Fluorescence in-situ hybridization; PR: Progesterone receptor; pT: Pathological tumor stage; PTEN: Phosphatase and tensin homolog; pN: Nodal stage; TMA: Tissue microarray.

Competing interest

The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining this article.

Authors’ contributions

PL, EB, RS, and GS designed the study, and drafted the manuscript. UH, VM, AA and FJ participated in study design. WK, MK, OK, KH, BT performed FISH analysis and scoring. LT and AL participated in pathology data analysis. CH-M and RS performed statistical analysis. IW, LW, SM, SG, pp and CW participated in data interpretation, and helped to draft the manuscript. AM, RK, participated in data interpretation. All authors read and approved the final manuscript.

Acknowledgments

This work was supported by the Deutsche Forschungsgemeinschaft, Germany (DFG SI 1347/3-1). The authors appreciate the excellent technical support of Christina Koep, Sylvia Schnöger and Sasa Eghersadai.

Author details

1 Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 2 Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3 Department of Gynecology, Regio Clinic Pinneberg, Pinneberg, Germany. 4 Department of Gynecology, Regio Clinic Elmshorn, Elmshorn, Germany. 5 Department of Gynecology, Clinical Centre Itzehoe, Itzehoe, Germany. 6 Department of Pathology, Basel University Clinics, Basel, Switzerland. 7 Institute of Pathology, Clinical Centre Osnabrück, Osnabrück, Germany. 8 Breast Centre Osnabrück, Osnabrück, Germany.

Received: 9 February 2015 Accepted: 10 October 2015
Published online: 16 December 2015

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(6):69–80.
2. Homburger JA, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care. 2005;11(5):313–24.
3. Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu M, et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more lymph node metastases. Clin Cancer Res. 2005;11(24 Pt 1):8623–31.
4. Veen Lj v’t, Hai D, van de Vlijser MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–6.
5. Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene. 2005;24(50):7465–74.
6. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943–7.
7. Chen J, Li T, Liu Q, Jiao H, Yang W, Liu X, et al. Clinical and prognostic significance of HIF-1alpha, PTEN, CD44v6, and survivin for gastric cancer: a meta-analysis. PLoS One. 2014;9(3), e91842.
8. Jin C, Wang A, Chen J, Liu X, Wang G. Relationship between expression and prognostic ability of PTEN, STAT3 and VEGF-C in colorectal cancer. Exp Ther Med. 2012;4(6):633–9.
9. Shu H, Zhang H, Xu C, Zhao X. Clinicopathological research and expression of PTEN/PK3/Akt signaling pathway in non-small cell lung cancer. Zhongguo fei a zi zhi = Chin J Lung Cancer. 2009;12(8):889–92.

10. Robledo C, Garcia JL, Caballero D, Conde E, Aranz V, Flores T, et al. Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. Cancer. 2009;115(16):3728–37.

11. Optiz I, Soltmann A, Abecherli M, Hinterberger M, Probst-Hensch N, Stahel R, et al. PTEN expression is a strong predictor of survival in metastasized patients. Eur J Cardiothorac Surg. 2008;33(3):502–6.

12. Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Konkbil M, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol. 2012;181(2):401–12.

13. Noh WC, Kim YH, Kim MS, Kho JS, Kim HA, Moon NM, et al. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res Treat. 2008;101(3):477–83.

14. Iqbal J, Thakke AA, Cheek PP, Tse GM, Tan PH. Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer. Histopathology. 2010;56(4):562–9.

15. Lee JS, Kim HS, Kim YB, Lee MC, Lai QR, Sieranskowska G, et al. Comprehensive analysis of PTEN status in breast carcinomas. Int J Cancer. 2013;133(2):323–34.

16. Depowski RL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene product is associated with poor outcome in breast cancer. Mod Pathol. 2001;14(7):767–72.

17. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JF, Ellis IO. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol. 2004;204(1):95–100.

18. Knudsen ES, Pajak TF, Qeenan M, McCledon AK, Armon BD, Schwartz GF, et al. Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression. J Natl Cancer Inst. 2012;104(23):1825–36.

19. Song CH, Park SY, Eom KY, Kim JH, Kim SW, Kim JS, et al. Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers. Breast Cancer Res Treat. 2010;122(2):R20.

20. Tural D, Serdengecti S, Demirelli F, Ozturk T, Ilvan S, Tuma H, et al. Clinical significance of p53/HER2 overexpression, PTEN loss and PIK3X expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Br J Cancer. 2014;110(8):1968–76.

21. Wang Y, Liu Y, Du Y, Yin W, Lu J. The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphatidylinositol (PI3K) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis. Curr Med Res Opin. 2013;29(6):633–42.

22. Park YH, Jung HA, Choi MK, Chang W, Choi YL, Do IG, et al. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (IMC) who received taxane plus trastuzumab treatment. Br J Cancer. 2014;110(2):384–91.

23. Ruiz C, Seibt S, Al Kuraya K, Siraj AK, Mihlarch M, Schraml P, et al. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer. 2006;118(9):2190–100.

24. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The relationship of histological grade to survival in breast cancer patients measured 20 years after treatment. Histopathology. 1991;19:403–410. Histopathology. 2002;40(3):315–22. discussion 315–22.

25. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 2004;64(23):8534–40.

26. Neto JC, Iokma MM, Canvalho KC, Vassallo J, De Brot M, Gobbi H, et al. MGMT and PTEN as potential prognostic markers in breast cancer. Exp Mol Pathol. 2010;89(2):162–9.

27. Ruiz E, Bobos M, Koutoula V, Eleftherakis AG, Kalofonos HP, Pavlakis V, et al. Evaluation of the association of PIK3CA mutations and PTEN loss with outcome in aggressive diffuse large B-cell lymphomas. Cancer. 2009;114(15):3722–37.

28. Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2012;16(3):348–59.

29. Toole SA, Mcneil CM, Millar EK, Qiu MM, Crea P, et al. Distinguishing medullary carcinoma of the breast from high-grade receptor-negative invasive ductal carcinoma: an immunohistochemical approach. Histopathology. 2010;56(7):852–9.

30. Perez-Tenorio G, Alkohl O, Olsson B, Weltertertse MA, Nordenskold B. Rutvist LE, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res. 2007;13(12):3577–84.

31. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, et al. Breast cancer cells addicted to Akt signaling. PLoS One. 2008;3(8), e3065.

32. Lopez-Knoelles E, O’Toole SA, McNeil CM, Miller ER, Qin MR, Crea P, et al. PIK3 pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer. 2010;126(5):1211–31.

33. Shuman N, Klassen S, McFadden A, Bicks MG, Tolakiiovic E, Chibbar R. Reduced PTEN expression predicts relapse in patients with breast cancer treated with tamoxifen. Mod Pathol. 2005;18(2):250–9.

34. Cao M, Cole MD. MYC acts via the PTEN tumor suppressor to elict autoregeneration and genome-wide gene expression by activation of the Ezh2 methyltransferase. Cancer Res. 2013;73(2):695–705.

35. She QB, Chandarlapaty S, Ye Q, Lobo J, Haikell KM, Leander KR, et al. Breast tumor cells with PIK3X mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One. 2008;3(8), e3065.

36. De P, Hasmann M, Leyland-Jones B. Molecular determinants of trastuzumab efficacy: what is their clinical relevance? Cancer Treat Rev. 2013;39(9):825–34.

37. Nagata Y, Kan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6(2):117–27.

38. Fujita T, Doihara H, Kawasaki K, Takabatake D, Takashiki H, Washio K, et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer. 2006;94(6):247–52.

39. Gallardo A, Lema E, Escuin D, Tabia A, Munoz J, Ojeda B, et al. Increased signalling of EGFR and cdk12 and deregulation of PTEN/PK3/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer. 2012;106(8):1367–73.

40. Berns K, Horlings HM, Hennessy BT, Madrero J, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12(4):395–402.
51. Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010;177(4):1647–56.

52. Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, et al. EGFR, pMAPK, pAKT and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol. 2009;20(4):648–54.

53. Shen WH, Balajeas WS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128(1):157–70.

54. Rudy DY, Levi PE, Fernandez-Salguero P, Gonzalez FJ, Hodgson E, Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 181 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver. Mol Pharmacol. 1996;50(3):443–6.

55. Little KC, Charron P. Genomic DNA is captured and amplified during double-strand break (DSB) repair in human cells. Oncogene. 2004;23(23):4166–72.

56. Courjal F, Theillet C. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. Cancer Res. 1997;57(19):4368–77.

57. Courjal F, Curyn M, Simony-Lafontaine J, Louasson G, Speiser P, Zeillinger R, et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res. 1997;57(19):4360–7.

58. Melchor L, Alvarez S, Honrado E, Palacios J, Barroso A, Diez O, et al. The accumulation of specific amplifications characterizes two different genomic pathways of evolution of familial breast tumors. Clin Cancer Res. 2005;11(24 Pt 1):8577–84.

59. Albertson DG. Gene amplification in cancer. TIG. 2006;22(1):447–55.

60. Roy PG, Pratt N, Purdie CA, Baker L, Ashfield A, Quinlan P, et al. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer. Int J Cancer. 2010;127(2):355–63.

61. Linke SP, Bremer TM, Herold CD, Sauter G, Diamond C. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. Clin Cancer Res. 2006;12(4):1175–83.

62. Prall OW, Rogan EM, Sutherland RL. Estrogen regulation of cell cycle progression in breast cancer cells. J Steroid Biochem Mol Biol. 1998;65(1–6):169–74.

63. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993;7(5):812–21.

64. Du MJ, Chen XD, Zhou XL, Wan YJ, Lan B, Zhang GZ, et al. Estrogen induces vav1 expression in human breast cancer cells. PLoS One. 2014(6), e99062.

65. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet. 1998;19(4):348–55.

66. Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco BI, et al. Nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128(1):157–67.

67. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A. 1999;96(4):1563–8.

68. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, et al. Cooperation of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009;41(5):524–52.

69. Krohn A, Seidel A, Burkhardt L, Bachmann F, Mader M, Grupp K, et al. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. J Pathol. 2013;231(1):30–41.

70. Menon R, Deng M, Boehm D, Braun M, Fend F, Boehm D, et al. Exome enrichment and SOLID sequencing of formalin fixed paraffin embedded (FFPE) prostate cancer tissue. Int J Mol Sci. 2012;13(7):8993–42.